Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Ovarian Neoplasms 3Breast Neoplasms 3Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Platinum-resistant Recurrent Ovarian Cancer 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14Cyclophosphamide 9Prednisone 8Etoposide 6Vincristine 5Gemcitabine 5Lenalidomide 4Doxorubicin 4Dexamethasone 3Azacitidine 3liposomal doxorubicin 2endostar protein 2apatinib 2VAP-cyclo protocol 2Ifosfamide 2Cisplatin 2sintilimab 1romidepsin 1ivarmacitinib 1fludarabine phosphate 1fludarabine 1camrelizumab 1Vinorelbine 1Valproic Acid 1Transplantation, Autologous 1TQ-B3525 1Rituximab 1Prednisolone 1Polymerase Chain Reaction 1Oxaliplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma, T-Cell, Peripheral × 1-dodecylpyridoxal × Clear all
NCT03952572 2019-05-16

Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma

Peking University

Phase 3 Unknown
244 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡